Orlistat PD Endpoint BE study [Regulatives / Guidelines]

posted by NK – India, 2024-04-30 06:33 (434 d 11:40 ago) – Posting: # 23966
Views: 1,965

Dear All,

As per the USFDA recommendation, if we conduct the Orlistat PD Endpoint BE study, we may have data (fecal fat) for Baseline, Test, Ref1 and Ref2

Can anyone explain how to analyze the pharmacodynamic study data step by step? how to establish dose response relationship?. Any example dataset are available?

Kindly suggest, which software (WinNonlin/SAS/etc…) is required to analyze these data.

Regards
NK

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,697 registered users;
46 visitors (0 registered, 46 guests [including 16 identified bots]).
Forum time: 18:14 CEST (Europe/Vienna)

Anyone who conducts an argument by appealing to authority
is not using his intelligence;
he is just using his memory.    Leonardo da Vinci

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5